var data={"title":"Ceftazidime: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ceftazidime: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5845?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">see &quot;Ceftazidime: Drug information&quot;</a> and <a href=\"topic.htm?path=ceftazidime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ceftazidime: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147933\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fortaz;</li>\n      <li>Fortaz in D5W;</li>\n      <li>Tazicef</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147934\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ceftazidime For Injection;</li>\n      <li>Fortaz</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046099\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (Third Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442226\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: IV: 30 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing (<i>Red Book</i> [AAP 2015]): IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight &lt;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;14 days: 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 15 to 28 days: 50 mg/kg/dose every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight 1 to 2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;7 days: 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 8 to 28 days: 50 mg/kg/dose every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight &gt;2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;7 days: 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 8 to 28 days: 50 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis</b> (Tunkel 2004): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &le;7 days: 100 to 150 mg/kg/day divided every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &gt;7 days: 150 mg/kg/day divided every 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046092\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">see &quot;Ceftazidime: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Infants and Children: 30 to 50 mg/kg/dose every 8 hours; maximum daily dose: 6 <b>g</b>/<b>day</b>; higher doses typically reserved for immunocompromised patients, cystic fibrosis, or meningitis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate infections: 90 to 150 mg/kg/day divided every 8 hours; maximum daily dose: 3,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe infections: 200 mg/kg/<b>day</b> divided every 8 hours; maximum daily dose: 6 <b>g</b>/<b>day</b>; higher doses (300 mg/kg/<b>day</b>) have been recommended for cystic fibrosis patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, lung infection caused by <i>Pseudomonas</i> spp:</b> Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/day divided every 6 to 8 hours (Bradley 2017); maximum daily dose: 6 <b>g</b>/<b>day</b>; higher doses have been used: 200 to 400 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 12 <b>g</b>/<b>day</b> (Zobell 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment:</b> Children and Adolescents: IV: 100 to 150 mg/kg/<b>day</b> divided every 8 hours; maximum daily dose: 4,000 mg/<b>day</b>; use in combination with gentamicin or vancomycin and gentamicin (plus rifampin if prosthetic material is present) depending on the cause of infection (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infections, complicated:</b> Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours in combination with metronidazole; maximum daily dose: 6 <b>g</b>/<b>day</b> (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b> Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every 8 hours; maximum daily dose: 6 <b>g</b>/<b>day</b> (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis)</b>: Infants, Children, and Adolescents: Intraperitoneal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent: 20 mg/kg/dose every 24 hours in the long dwell (ISPD [Warady 2012]); in adults, intermittent: 1,000 to 1,500 mg every 24 hours per exchange in the long dwell (&ge;6 hours) (Li 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous: Loading dose: 500 mg per liter of dialysate; maintenance dose: 125 mg per liter (ISPD [Warady 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection:</b> Infants and Children 2 to 24 months: IV: 100 to 150 mg/kg/day divided every 8 hours (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: IV: 90 to 150 mg/kg/<b>day</b> every 8 hours; maximum daily dose: 6 <b>g</b>/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternative recommendations: IV: 200 to 400 mg/kg/<b>day</b> divided every 6 to 8 hours (maximum daily dose: 8 to 12 <b>g</b>/<b>day</b>); <b>or</b> by continuous IV infusion: 100 to 200 mg/kg/<b>day</b> (maximum daily dose: 12 <b>g</b>/<b>day</b>) (Zobell 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Empiric therapy in immunocompromised patients:</b> IV: 2,000 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Uncomplicated: IM, IV: 500 to 1,000 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hospital-acquired or ventilator-associated: IV: 2,000 mg every 8 hours for 7 days; may consider shorter or longer duration depending on rate of clinical improvement. When used as empiric therapy, use in combination with an agent active against <i>S. aureus</i> with or without an additional antipseudomonal agent (dependent on patient and institution-specific risk factors) (ATS/IDSA [Kalil 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue infections:</b> IV, IM: 500 mg to 1,000 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Severe infections, including meningitis, CNS infection, osteomyelitis, gynecological:</b> IV: 2,000 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Uncomplicated: IV, IM: 250 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Complicated: IV, IM: 500 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: The manufacturer recommends decreasing dosing frequency based on the calculated BSA-adjusted creatinine clearance. The following guidelines have been used by some clinicians (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on a usual dose of 25 to 50 mg/kg/dose every 8 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 50 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 50 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Dialyzable (50% to 100%): 50 mg/kg/dose every 48 hours, give after dialysis on dialysis days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: 50 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: <b>Note:</b> If the dose recommended in the dosing section is lower than that recommended for patients with renal insufficiency as outlined below, the lower dose should be used. In severe infections, when the usual dose would be ceftazidime 6 g/day in patients without renal impairment, consider increasing the doses below by 50% or increase the dosing frequency. Further dosage adjustments should be determined by infection severity, susceptibility, and patient response to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 31 to 50 mL/minute: Administer 1,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 16 to 30 mL/minute: Administer 1,000 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 6 to 15 mL/minute: Administer 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &le;5 mL/minute: Administer 500 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (50% to 100%): 500 to 1,000 mg every 24 hours <b>or</b> 1,000 to 2,000 mg every 48 to 72 hours (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times per week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent: Loading dose of 1,000 mg, followed by 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous: Loading dose of 1,000 mg, followed by 500 mg every 24 hours. <b>Note:</b> An additional 125 mg per liter of exchange fluid may be added to the dialysate if clinically warranted.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVH: Loading dose of 2,000 mg followed by 1,000 to 2,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVHD/CVVHDF: Loading dose of 2,000 mg followed by either 1,000 mg every 8 hours <b>or </b>2,000 mg every 12 hours. <b>Note:</b> Dosage of 1,000 mg every 8 hours results in similar steady-state concentrations as 2,000 mg every 12 hours and is more cost effective. Dosage of 2,000 mg every 8 hours may be needed for gram-negative rods with MIC &ge;4 mg/L (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> For patients receiving CVVHDF, some recommend giving a loading dose of 2,000 mg followed by 3,000 mg over 24 hours as a continuous IV infusion to maintain concentrations &ge;4 times the MIC for susceptible pathogens (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No adjustment required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147911\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortaz in D5W: 1 g (50 mL); 2 g (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazicef: 1 g/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortaz: 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea); 6 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazicef: 1 g (1 ea); 2 g (1 ea); 6 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 6 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 6 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortaz: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazicef: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/50 mL (1 ea); 2 g/50 mL (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147895\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046102\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Inadvertent intra-arterial administration may result in distal necrosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IVP: Administer over 3 to 5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermittent IV infusion: Administer over 15 to 30 minutes  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3051221\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vials: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Reconstituted solution and solution further diluted for IV infusion are stable for 24 weeks when immediately frozen at -20&deg;C (-4&deg;F). After freezing, thawed solution in NS in a Viaflex small volume container for IV administration is stable for 24 hours at room temperature or for 7 days when refrigerated. Do not refreeze the thawed solution. Ceftazidime solutions (concentrations 1 to 40 mg/mL) in NS, D<sub>5</sub>W, D<sub>5</sub>NS, LR, D<sub>10</sub>W, Ringer's injection, or SWFI are stable for 24 hours at room temperature (20&deg;C to 25&deg;C [68&deg;F to 77&deg;F]) and for 7 days if refrigerated (4&deg;C [39&deg;F]).  Consult detailed reference regarding stability of ceftazidime in other solutions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duplex container: Store unactivated containers at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. Do not freeze. Unactivated duplex containers with foil strip removed from the drug chamber must be protected from light and used within 7 days at room temperature. Once activated, must be used within 12 hours if stored at room temperature or within 3 days if stored under refrigeration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Premixed frozen solution: Store at -20&deg;C (-4&deg;F). Thawed solution is stable for 8 hours at room temperature or for 3 days under refrigeration; do not refreeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046101\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of susceptible infections of the respiratory tract, urinary tract, gynecologic, skin and skin structure, intra-abdominal, osteomyelitis, sepsis, and meningitis (FDA approved in all ages). Has also been used in treatment of peritonitis in patients with peritoneal catheters and for the treatment of endocarditis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147987\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CefTAZidime may be confused with ceFAZolin, cefepime, cefoTEtan, cefOXitin,  cefTRIAXone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ceptaz may be confused with Septra</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazicef may be confused with Tazidime</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ceftim [Portugal] and Ceftime [Thailand] brand names for ceftazidime may be confused with Ceftin brand name for cefuroxime [U.S., Canada]; Cefiton brand name for cefixime [Portugal]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147984\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase, increased lactate dehydrogenase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, eosinophilia, leukopenia, lymphocytosis, neutropenia, positive direct Coombs test (without hemolysis), thrombocythemia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reactions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Inflammation at injection site, injection site phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal pain, anaphylaxis (severe in rare instances, including cardiopulmonary arrest), angioedema, candidiasis, <i>Clostridium difficile</i> associated diarrhea, dizziness, erythema multiforme, headache, hemolytic anemia, hyperbilirubinemia, jaundice, nausea, pain at injection site, paresthesia, renal insufficiency, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vaginitis, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147918\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Clinically significant hypersensitivity to ceftazidime, other cephalosporins, penicillins, other beta-lactam antibiotics, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147899\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: High ceftazidime levels in patients with renal insufficiency can lead to seizures, encephalopathy, coma, asterixis, myoclonia, and neuromuscular excitability. Reduce total daily dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298996\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147904\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13134&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May diminish the therapeutic effect of CefTAZidime. Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147907\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5951787\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Ceftazidime crosses the placenta and reaches the cord serum and amniotic fluid. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins. Maternal peak serum concentration is unchanged in the first trimester. After the first trimester, serum concentrations decrease by approximately 50% of those in nonpregnant patients. Renal clearance is increased during pregnancy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046098\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function periodically when used in combination with aminoglycosides; with prolonged therapy also monitor hepatic and hematologic function periodically; number and type of stools/day for diarrhea. Observe for signs and symptoms of anaphylaxis during first dose. Monitor prothrombin time in patients at risk for increased INR (nutritionally deficient patients, prolonged treatment, hepatic or renal disease)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147898\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147917\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely throughout the body including bone, bile, skin, CSF (higher concentrations achieved when meninges are inflamed), endometrium, heart, pleural and lymphatic fluids </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;10% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1 to 2 hours, prolonged with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: ~1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80% to 90% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323051\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Tazicef Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (50 mL): $16.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefTAZidime and Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (1): $12.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 gm/50 mL (1): $17.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefTAZidime Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $6.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 g (1): $35.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Tazicef Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $5.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $11.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 g (1): $36.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Tazicef Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $6.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $13.07</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147923\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Baxidyme (PH);</li>\n      <li>Biotum (PL, UA);</li>\n      <li>Biozim (ID);</li>\n      <li>Caltum (ID);</li>\n      <li>Cef-H (MY);</li>\n      <li>Cefa 3 (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cefadime (TW);</li>\n      <li>Cefatum (MY);</li>\n      <li>Cefaz (HR);</li>\n      <li>Cefazime (SG);</li>\n      <li>Cefdim (ID);</li>\n      <li>Cefortam (PT);</li>\n      <li>Cefpiran (PE);</li>\n      <li>Cefranz (PH);</li>\n      <li>Ceftamil (RO);</li>\n      <li>Ceftaz (LK);</li>\n      <li>Ceftazash (ET);</li>\n      <li>Ceftazivit (VN);</li>\n      <li>Ceftidin (IN);</li>\n      <li>Ceftim (IT, PT);</li>\n      <li>Ceftum (ID, JO);</li>\n      <li>Celodim (ID);</li>\n      <li>Cestazid (PH);</li>\n      <li>Cetazine (TW);</li>\n      <li>Cetazum (ID);</li>\n      <li>Cezidin (MT);</li>\n      <li>Dimcef (KR);</li>\n      <li>Dimzef (PH);</li>\n      <li>Elzid (LK);</li>\n      <li>Extimon (ID);</li>\n      <li>Fivtum (PH);</li>\n      <li>Fortam (CH, ES, UY);</li>\n      <li>Fortaz (BR);</li>\n      <li>Fortum (AE, AR, AT, AU, BB, BF, BG, BH, BJ, BM, BS, BZ, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ET, FR, GB, GH, GM, GN, GT, GY, HK, HN, HU, ID, IE, IL, IN, IQ, IR, IS, JM, JO, KE, KR, KW, LB, LK, LR, LT, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PR, PY, QA, RO, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Fortum Pro (HN);</li>\n      <li>Fortumset (FR);</li>\n      <li>Forzid (PH);</li>\n      <li>Ftazidime (GR);</li>\n      <li>Glazidim (BE, FI, IT, LU);</li>\n      <li>Izadima (DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Kabi (UA);</li>\n      <li>Kefadim (BF, BJ, CI, ET, GH, GM, GN, KE, LR, LU, MA, ML, MR, MU, MW, NE, NG, PK, SC, SD, SL, SN, TN, TW, TZ, UG, VN, ZA, ZM, ZW);</li>\n      <li>Kefazim (AT);</li>\n      <li>Kefzim (CL);</li>\n      <li>Lacedim (ID);</li>\n      <li>Lemoxol (NZ);</li>\n      <li>Maxidim (BD);</li>\n      <li>Megacef (PH);</li>\n      <li>Mirocef (HR);</li>\n      <li>Negacef (AE, BH, KW, LB, QA, SA);</li>\n      <li>Orzid (ET);</li>\n      <li>Pharodime (ID);</li>\n      <li>Romacef (PH);</li>\n      <li>Septax (IL);</li>\n      <li>Solvetan (GR);</li>\n      <li>Spectrum (IT);</li>\n      <li>Starcef (IT);</li>\n      <li>Tagal (MX);</li>\n      <li>Tazicef (KR, PH);</li>\n      <li>Tazidan (PH);</li>\n      <li>Tazidem (PH);</li>\n      <li>Tazime (CN, KR, SG);</li>\n      <li>Thidim (ID);</li>\n      <li>Tinacef (AR, PY);</li>\n      <li>Trizidim (BD);</li>\n      <li>Trofiz (UA);</li>\n      <li>UIzadima (CR);</li>\n      <li>Yadim (HK);</li>\n      <li>Zadolina (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Zeptrigen (PH);</li>\n      <li>Zibac (ID);</li>\n      <li>Zidd (UA);</li>\n      <li>Zidimax (BD);</li>\n      <li>Zidime (AE, JO, KW, QA);</li>\n      <li>Zidmbiotic (VN);</li>\n      <li>Zitadim (ID);</li>\n      <li>Zitum (BD);</li>\n      <li>Zytaz (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP), &quot;Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months,&quot; <i>Pediatrics</i>, 2011, 128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Assael BM, Boccazzi A, Caccamo ML, et al. Clinical pharmacology of ceftazidime in paediatrics. <i>J Antimicrob Chemother</i>. 1983;(12 Suppl A):341-346.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/6352640/pubmed\" target=\"_blank\" id=\"6352640\">6352640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boccazzi A, Rizzo M, Caccamo ML, et al, &quot;Comparison of the Concentrations of Ceftazidime in the Serum of Newborn Infants After Intravenous and Intramuscular Administration,&quot; <i>Antimicrob Agents Chemother</i>, 1983, 24(6):955-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/6362562/pubmed\" target=\"_blank\" id=\"6362562\">6362562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortaz (ceftazidime) [prescribing information]. Cary, NC: Covis Pharmaceuticals; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld AG, Bow EJ, Sepkowitz KA, et al, &quot;Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer: 2010 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2011, 52(4):e56-93.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes WT, Armstrong D, Bodey GP, et al, &quot;2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer,&quot; <i>Clin Infect Dis</i>, 2002, 34(6):730-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/11850858/pubmed\" target=\"_blank\" id=\"11850858\">11850858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. <i>Perit Dial Int</i>. 2010;30(4):393-423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/20628102/pubmed\" target=\"_blank\" id=\"20628102\">20628102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsitz R, Garges S, Aurigemma R, et al. Workshop on treatment of and postexposure prophylaxis for <i>Burkholderia pseudomallei</i> and <i>B. mallei</i> infection, 2010. <i>Emerg Infect Dis</i>. 2012;18(12):e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/23171644/pubmed\" target=\"_blank\" id=\"23171644\">23171644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Low DC, Bissenden JG, and Wise R, &quot;Ceftazidime in Neonatal Infections,&quot; <i>Arch Dis Child</i>, 1985, 60(4):360-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/3890766/pubmed\" target=\"_blank\" id=\"3890766\">3890766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCracken GH Jr, Threlkeld N, and Thomas ML, &ldquo;Pharmacokinetics of Ceftazidime in Newborn Infants,&rdquo; <i>Antimicrob Agents Chemother</i>, 1984, 26(4):583-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/6393862/pubmed\" target=\"_blank\" id=\"6393862\">6393862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulhall A and de Louvois J, &quot;The Pharmacokinetics and Safety of Ceftazidime in the Neonate,&quot; <i>J Antimicrob Chemother</i>, 1985, 15(1):97-103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/3882658/pubmed\" target=\"_blank\" id=\"3882658\">3882658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson DC, Cookson TL, and Grisafe JA, &ldquo;Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients,&rdquo; <i>Drug Intell Clin Pharm</i>, 1987, 21(12):985-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/3428165/pubmed\" target=\"_blank\" id=\"3428165\">3428165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tazicef (ceftazidime) [prescribing information]. Lake Forest, IL: Hospira; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tessin I, Trollfors B, Thiringer K, et al, &quot;Concentrations of Ceftazidime, Tobramycin and Ampicillin in the Cerebrospinal Fluid of Newborn Infants,&quot; <i>Eur J Pediatr</i>, 1989, 148(7):679-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/2663518/pubmed\" target=\"_blank\" id=\"2663518\">2663518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Anker JN, Hop WC, Schoemaker RC, et al, &quot;Ceftazidime Pharmacokinetics in Preterm Infants: Effect of Postnatal Age and Postnatal Exposure to Indomethacin,&quot; <i>Br J Clin Pharmacol</i>, 1995, 40(5):439-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/8703647/pubmed\" target=\"_blank\" id=\"8703647\">8703647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Anker JN, Schoemaker RC, van der Heijden BJ, et al, &quot;Once-Daily Versus Twice-Daily Administration of Ceftazidime in the Preterm Infant,&quot; <i>Antimicrob Agents Chemother</i>, 1995a, 39(9):2048-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/8540714/pubmed\" target=\"_blank\" id=\"8540714\">8540714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, 32(Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Waters CD, Young DC, et al, &quot;Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: II. Cephalosporins and Penicillins,&quot; <i>Pediatr Pulmonol</i>, 2013, 48(2):107-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftazidime-pediatric-drug-information/abstract-text/22949297/pubmed\" target=\"_blank\" id=\"22949297\">22949297</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13134 Version 164.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F147933\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F147934\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046099\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442226\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046092\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147911\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F147895\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046102\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F3051221\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046101\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147987\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147984\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147918\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147899\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298996\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147904\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147907\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5951787\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046098\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147898\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F147917\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323051\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F147923\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13134|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">Ceftazidime: Drug information</a></li><li><a href=\"topic.htm?path=ceftazidime-patient-drug-information\" class=\"drug drug_patient\">Ceftazidime: Patient drug information</a></li></ul></div></div>","javascript":null}